Coronary microvascular obstruction in acute myocardial infarction

Eur Heart J. 2016 Apr 1;37(13):1024-33. doi: 10.1093/eurheartj/ehv484. Epub 2015 Sep 12.

Abstract

The success of a primary percutaneous intervention (PCI) in the setting of ST elevation myocardial infarction depends on the functional and structural integrity of coronary microcirculation. Coronary microvascular dysfunction and obstruction (CMVO) occurs in up to half of patients submitted to apparently successful primary PCI and is associated to a much worse outcome. The current review summarizes the complex mechanisms responsible for CMVO, including pre-existing coronary microvascular dysfunction, and highlights the current limitations in the assessment of microvascular function. More importantly, at the light of the substantial failure of trials hitherto published on the treatment of CMVO, this review proposes a novel integrated therapeutic approach, which should overcome the limitations of previous studies.

Keywords: Acute myocardial infarction; Microvascular dysfunction; Microvascular obstruction.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiac Catheterization / methods
  • Coronary Occlusion / diagnosis
  • Coronary Occlusion / etiology*
  • Coronary Occlusion / therapy
  • Disease Models, Animal
  • Disease Susceptibility / complications
  • Drug Therapy, Combination
  • Embolism / etiology
  • Embolism / physiopathology
  • Glucose / therapeutic use
  • Humans
  • Insulin / therapeutic use
  • Microcirculation / physiology
  • Myocardial Reperfusion Injury / etiology
  • Myocardial Reperfusion Injury / physiopathology
  • Percutaneous Coronary Intervention / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use
  • Potassium / therapeutic use
  • Prognosis
  • ST Elevation Myocardial Infarction / etiology*
  • ST Elevation Myocardial Infarction / therapy
  • Swine

Substances

  • Insulin
  • Platelet Aggregation Inhibitors
  • glucose-insulin-potassium cardioplegic solution
  • Glucose
  • Potassium